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Inhibition of AMP deaminase (AMPD) holds the po-
tential to elevate intracellular adenosine and AMP
levels and, therefore, to augment adenosine signaling
and activation of AMP-activated protein kinase
(AMPK). To test the latter hypothesis, novel AMPD
pan inhibitors were synthesized and explored using
apanel of in vitro, ex vivo, and in vivomodels focusing
on confirming AMPD inhibitory potency and the po-
tential of AMPD inhibition to improve glucose control
in vivo. Repeateddosingof selected inhibitors did not
improve glucose control in insulin-resistant or dia-
betic rodent disease models. Mice with genetic dele-
tion of the muscle-specific isoform Ampd1 did not
showany favorablemetabolic phenotype despite be-
ing challenged with high-fat diet feeding. Therefore,
these results do not support the development of
AMPD inhibitors for the treatment of type 2 diabetes.
INTRODUCTION
AMP-metabolizing enzymes play an important role in maintain-
ing adenine nucleotide homeostasis and cellular energy charge
in situations of ATP depletion (Chen et al., 1996). Adenylate ki-
nase responds to transient drops in energy charge by catalyzing
the conversion of two ADP to ATP and AMP, thereby counteract-
ing the lowering of ATP concentration and simultaneously pre-
venting ADP levels from rising. The AMP formed is, in turn,
involved in the stimulation of catabolic pathways, many of which
are coordinated by AMP-activated protein kinase (AMPK). AMP
is then either deaminated via AMP deaminase (AMPD) to inosine
monophosphate (IMP) or hydrolyzed to adenosine (via 50-nucle-
otidase). Therefore, inhibition of both 50-nucleotidase and AMPD
has the potential to elevate AMP levels, cause downstream acti-
vation of AMPK, and boost catabolic pathways.
AMPK plays a central role in the regulation of cellular energy
charge. It is activated by increases in AMP and ADP levels and,
therefore, reacts to counteract energy deprivation (Oakhill et al.,1486 Chemistry & Biology 21, 1486–1496, November 20, 2014 ª20142011, 2012). AMPK phosphorylates and regulates several key
metabolic enzymes to favor ATPproduction and, simultaneously,
slow down anabolic pathways such as protein and fatty acid syn-
thesis (for reviews, see Carling et al., 2012; Hardie et al., 2012b).
Not surprisingly, during recent years, several direct and indirect
AMPK activators have been reported to act as metabolic modu-
lators (Giordanetto and Karis, 2012; Zhou et al., 2009). AMPK ex-
ists as variants of ana,b,gheterotrimer (a total of 2a subunits, 2b
subunits, and 3 g subunits, giving rise to a total of 12 possible
combinations) with different tissue distribution. Most tissues
contain several AMPK variants, making it challenging to design
organ-specific activators (see Viollet et al. (2010) and references
therein). Analternative approachcouldbe tomodulate theactivity
of tissue-specific adenine nucleotide-metabolizing enzymes. In-
hibition of these enzymes has the potential to elevate intracellular
levels of AMP and, as a consequence, activate AMPK (Kulkarni
et al., 2011; Plaideau et al., 2012). However, data from multiple
dosing studies using well tolerated AMPD or 50-nucleotidase in-
hibitors in vivo have been lacking.
There are three different AMP deaminase, AMPD1, AMPD2,
and AMPD3 isozymes with different tissue expression. In hu-
mans, AMPD1 is mainly found in skeletal muscle and, to some
extent, in the heart. AMPD2 is expressed in the liver and brain,
whereas both AMPD2 and AMPD3 are present in the heart, kid-
ney, and spleen (Ogasawara et al., 1982). Erythrocytes mainly
express the isoform AMPD3 (Ogasawara et al., 1982). Human
AMPD1 deficiency leads to various muscle phenotypes, ranging
from mild fatigue to myopathies with more marked differences
observed when subjects with hetero- or homozygote mutations
are compared with normal controls after acute and intense
muscle exercise (Engel et al., 1964; Fishbein et al., 1978; Norman
et al., 2001; Sabina et al., 1980).
Potent coformycin analog AMPD inhibitors have been
described (Erion et al., 1999; Kasibhatla et al., 1998), but with
the liability of having limited cell permeability (Borkowski et al.,
2008a, 2008b), thereby restricting their use in oral multidosing
studies. More recently, the widely used antidiabetic drugmetfor-
minwas also demonstrated to act as anAMPD inhibitor, although
at millimolar concentrations and in in vitro models (Ouyang et al.,
2011). Here we present a series of orally available AMPD pan in-
hibitors that potently inhibit AMPDactivity in tissue homogenates
aswell as in intact cells. Examples from this serieswere also usedElsevier Ltd All rights reserved
Figure 1. High-Throughput Screen and Hit Confirmation for the
Identification of AMPD1 Inhibitors
(A) Schematic showing the AMPD assay. a-KG, a-ketoglutarate.
(B) Z’ factors of each run through the HTS.
(C) The correlation between the negative logarithm of the IC50 (pIC50) from the
HTS assay and the counterscreen. The x axis is the counterscreen, and the y
axis is the HTS assay.
(D) Correlation between three-point and seven-point concentration responses.
The x axis shows seven-point data, and the y axis shows three-point data.
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AMPD Inhibitors and Genetic Ampd1 Deletionfor repeated dosing in obese, diabetic ob/ob mice as well as in
insulin-resistant, diet-induced obese (DIO) mice at exposure
levels above that required to inhibit the AMPD enzymes in intact
cells as well as in tissue homogenates. No improvements in
glucose control were observed in either of the disease models.
Furthermore, no beneficial metabolic phenotype was observed
in mice with genetic deletion of Ampd1 when fed a standard
chow or when fed a high-fat diet. We also confirm that metformin
indeed caused inhibition of the AMPD1andAMPD2 isoforms, but
the effect was rather weak and only significant at suprapharma-
cological concentrations of metformin.
RESULTS
HTS Screen and Hit Confirmation for Identification of
AMPD1 Inhibitors
To identify AMPD1 inhibitors, an assay was developed suitable
for 1,536-well high-throughput screening (HTS). The coupledChemistry & Biology 21, 1486–149assay allowed ammonia formed in the AMPD reaction to be
used by glutamate dehydrogenase (GDH) to convert the reduced
form of nicotinamide adenine dinucleotide phosphate (NADPH)
to nicotinamide adenine dinucleotide phosphate (NADP+), which
was monitored by a decrease in absorbance at 340 nm (Fig-
ure 1A). A total of 884,000 compounds were analyzed. The assay
quality was good to excellent, with Z’ values (Zhang et al., 1999)
ranging from 0.45–0.9 in the different runs (Figure 1B). The hit
rate was around 1.9%, and all hits were selected for three-point
concentration response (CR). A counterscreen based on adding
ammonia instead of AMPD1 to mimic the second part of the re-
action in Figure 1A was employed. This assay ensured the
removal of compounds that interfered with the coupling reaction.
The results showed that more than 95% of the tested com-
pounds interfered with the second part of the reaction or the
detection (Figure 1C). About 250 compounds of interest were
selected for seven-point CR testing to investigate the correlation
with the previously obtained three-point CR data. The correlation
observed was considered to be good, but there were some
deviations (Figure 1D). For all further work, seven-point CR
data were used.
Properties and Optimization of Series 106
A racemate of compound 1 (Figure 2B) was confirmed as a low
micromolar hit in the GDH-coupled seven-point CR assay
described above. Being chemically stable, selective against
closely related adenosine deaminase, and showing no similarity
to other AMPD inhibitors (Bojack et al., 1999; Erion et al., 1994), it
offered the potential for structural variations to build up a
structure-activity relationship (SAR) (Figure 2A). The (R)-enan-
tiomer of compound 1 was identified as the most potent isomer.
The lead identification phase focused on optimizing potency,
metabolic stability, and reactive metabolite formation (trapping
studies and assessment of acyl glucuronide stability) by control-
ling and lowering lipophilicity in the design of subsequent
compounds.
The zwitterionic character proved to be mandatory to retain
potency. Isosteric replacements of the carboxylic acid motif
with acidic H-bond donors resulted in a mild loss of inhibition,
whereas replacement with non-H-bond donors caused a signif-
icant drop in potency. Small changes to the aryl acid motif,
including substitution patterns and heterocyclic replacements,
were generally well tolerated. A Caco-2 monolayer model was
used to predict the fraction of the oral dose absorbed (fa). Exper-
iments were performed in an apical (pH 6.5) to basolateral
(pH 7.4) direction. Despite the zwitterionic character of the com-
pounds, the fa was predicted to be high. The less lipophilic com-
pounds were more prone to efflux, which, in combination with
glucuronidation in the gut, was, to some extent, limiting overall
the bioavailability/absorption in rats (physiologically based phar-
macokinetic simulations). However, the bioavailability was high
enough to achieve adequate exposure in the in vivo studies.
The common site of metabolism for the series of compounds
was oxidation of the secondary benzylic carbon, forming a
potentially reactive aldehyde that could be trapped by methoxyl
amine.
A steep SAR was observed around the amine functionality.
Switching to an amide was not tolerated, nor was the removal
of the methyl substituent or additional substitution, which all6, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1487
Figure 2. Properties and Optimization of
AMPD Inhibitors
(A) The structure-activity relationship for series 106.
(B) Structures for compounds 1, 2, 3, and 4.
(C) Direct comparison of the inhibitory action of
compound 2 (squares) and compound 3 (circles) in
ob/ob muscle homogenates (MH, open symbols,
n = 3) with recombinant murine AMPD1 (filled
symbols, n = 2, upper panel) as well as rat liver
extracts (LH, opensymbols, n=3) and recombinant
AMPD2 (filled symbols, n = 6, lower panel). The
values are mean ± SD.
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adducts to proteins in vivo were considered to carry a limited
risk for adverse reactions because of the apparent reversibility
of adduct formation. As a representative metabolite for the se-
ries, 6-(4-formylphenyl)nicotinic acid was tested and found to
be inactive for potential mutagenicity in Salmonella typhimurium
(Ames test) (Maron and Ames, 1983).
Acyl glucuronide conjugation was a minor metabolic pathway.
The reactivity of conjugates was assessed by estimation of the
half-life for migration of glucuronic acid. The conjugates for all
compounds testedwere stable or moderately stable and consid-1488 Chemistry & Biology 21, 1486–1496, November 20, 2014 ª2014 Elsevier Ltd All rights rered to be less reactive. The exchange of
the naphthalene moiety, identified as a
source of reactive metabolites trapped
by glutathione, by the more polar quino-
line resulted in an increased potency,
thus improving ligand lipophilicity effi-
ciency (LLE) by 2.5, and increasing meta-
bolic stability. Physicochemical proper-
ties of the AMPD inhibitors are
summarized in Table 1.
Concentration Response Data for
Recombinant Enzymes and Tissue
Homogenates
Table 2 shows potencies for the AMPD in-
hibitors as determined by concentration
response testing using recombinant hu-
man and rodent enzymes as well as mus-
cle and liver homogenates from Sprague
Dawley rats and ob/ob mice. Apparent
Km values for AMP in Sprague Dawley
rat muscle and liver homogenates were
found to be 1.2 and 5.5 mM, respectively.
Corresponding values for recombinant
rat AMPD1 and AMPD2 were 2.3 and
4.2 mM, respectively (data not shown).
Figure 2C, top panel, shows the data for
compound 2 and compound 3 (Figure 2B)
when tested in the GDH-coupled AMPD
assay using recombinant murine AMPD1
or muscle tissue homogenates from
ob/obmice. Compound 2 and compound
3 displayed rather similar half-maximal
inhibitory concentration (IC50) values forinhibition of the recombinant and native enzymes (4.5 versus
7 mM, respectively, for compound 2 and 0.024 versus
0.020 mM, respectively for compound 3) and, therefore, these en-
antiomers demonstrated a more than 200-fold separation in po-
tency in both assays. A comparison for the AMPD2 isoform is
shown in the bottom panel of Figure 2C, where the concentration
response data for compound 2 and compound 3 in assays using
either recombinant rat AMPD2 or rat liver tissue homogenates
are given. Both compounds appear to be 2- to 3-fold more
potent when tested on rat liver homogenates compared with
recombinant rat AMPD2. A similar result was observed witheserved
Table 1. Potency and Physicochemical Properties of the AMPD Inhibitors
Compound 1 Compound 2 Compound 3 Compound 4
hAMPD1 IC50 (mM) 0.62 ± 0.26 (n = 15) 9.2 ± 2.0 (n = 4) 0.038
a 0.024a
ClogP 4.91 3.41 3.41 3.99
logD7.4 1.9 0.5 0.5 0.8
LLE 4.3 4.5 6.8 6.8
Caco-2 papp (1E-6 cm/s)/ER 35/0.9 4.8/3.5 2.9/11 38/1.3
huHepClint (ml/min/1E6 cells) 11 <4.0 <4.9 <4.0
GSH/methoxyl amine conjugates yes/yes <LOQ/ND <LOQ/yes <LOQ/ND
Acyl glucuronide stability t1/2 (min) >180 ND 90 >>90
Bioavailability rat (%) 40 ND 29 64
hAMPD1, human recombinant AMPD1; LLE, ligand lipophilicity efficiency calculated as pIC50 – logD; ER, Caco-2 cell efflux ratio; GSH, glutathione;
LOQ, limit of quantitation; n, multiple independent experiments; ND, not determined.
aIC50 value resulting from four-parameter logistic fitting to duplicate data.
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tencies in tissue homogenates versus the recombinant enzymes.
This could possibly be due to recombinant enzyme concentra-
tions being higher than native enzymes in the tissue homoge-
nates (e.g., concentrations of mAMPD1 and rAMPD2 = 18 and
53 nM, respectively). If the active site concentration equals the
enzyme concentration in these cases, this may result in an
apparent lower potency because of compound depletion. Met-
formin has been reported to partially inhibit AMPD1 activity at
millimolar concentrations (Ouyang et al., 2011). Figure S1 (avail-
able online) shows the results from concentration response
testing up to 20 mM metformin in the rat AMPD1 and AMPD2
assays. The only significant effect was observed at 20 mM met-
formin, where AMPD1 and AMPD2 were inhibited by 27% and
28%, respectively.
AMPD Inhibition in ATP-Depleted Primary Rat
Hepatocytes
Compounds 2, 3, and 4 were tested for effects on nucleotide
levels following the protocol described by Erion et al. (1999)
using freshly prepared rat hepatocytes in suspension before
and after ATP depletion by addition of 0.5 mg/ml fructose
(2.8 mM). ATP reduction and IMP formation occurred instantly
and already reached amaximumafter 5min of fructose exposure
(Figure 3A). IMP levels increased from below the detection limit
to 4.5% of total nucleotides concomitant with fructose-induced
ATP depletion. Figure 3B shows the concentration response for
inhibition of IMP formation by compound 3 and compound 4with
an estimated IC50 < 0.5 mM for both compounds, which is in
agreement with the potencies seen in the rat liver homogenate
assay. As a result of inhibiting AMPD activity, the already high
AMP levels because of fructose phosphorylation became further
elevated, as seen in Figure 3C. Although both compound 3 and
compound 4 robustly inhibited IMP formation along with accom-
panying elevations in AMP, compound 3 appeared to be slightly
more potent, despite opposite ranking in the liver homogenate
assay. The inactive enantiomer, compound 2, had no significant
effects on nucleotide levels. Exposure to compounds 3 and 4
also decreased levels of the downstream nucleosides, inosine
and hypoxanthine, as a consequence of AMPD inhibition. How-
ever, variation in the adenosine levels was too large to see theChemistry & Biology 21, 1486–149expected rise in adenosine. None of the tested compounds
had any effects on adenine nucleotide levels prior to increasing
flux through AMPD following fructose-induced ATP depletion
(data not shown).
Repeated Dosing of DIO and ob/ob Mice with AMPD
Inhibitors
Two repeated dosing studies in disease models of insulin resis-
tance (DIOmice, compounds 2 and 3) and diabetes (ob/obmice,
compound 3) were performed. Table 3 summarizes the data from
the 2-week repeated dosing study in DIO mice with vehicle and
with compound 2 and compound 3, both dosed orally at
300 mmol/kg twice daily (b.i.d.). The plasma concentration
achieved for compound 2 and compound 3 (Table 3) corre-
sponded to an estimated average concentration unbound in
plasma of 0.2-fold or 50-fold above that of the mouse AMPD1
IC50 (Table 2), respectively, over the 2-week treatment period.
Similar exposure levels for compound 3 were shown to cause
AMPD inhibition in rat isolated muscle strips (see accompanying
article by Plaideau et al., 2014), therefore supporting the com-
pound’s ability to penetrate muscle tissue and into myotubes.
Body weight was reduced in all three groups during the
2-week dosing period, but the body weight reduction was not
significantly different between the vehicle- and compound-
treated groups (Table 3). Following 2 weeks of repeated dosing,
an oral glucose tolerance test (OGTT) was performed. Basal
glucose and insulin levels were increased in the compound
3-treated group at the start of the OGTT. Calculations of homeo-
static model assessment (HOMA) insulin resistance index
(glucose (millimolar) 3 insulin (pg/ml)) from the basal glucose
and insulin levels suggested an impairment in glucose control,
but the incremental area under the curve (AUC) for glucose
and insulin levels was not significantly different between any of
the cohorts (Table 3).
Dosing of compound 3 (300 mmol/kg/day, b.i.d.) to obese, dia-
betic ob/ob mice for 1 week resulted in a reduction in body
weight gain compared with vehicle-treated mice (Table S1).
Body weight gain decreased despite no difference in cumulative
food intake over the whole dosing period (vehicle control,
5.3 g/mouse/day; compound 3, 5.1 g/mouse/day, respectively).
Plasma glucose and insulin levels after 3 hr of fasting were6, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1489
Table 2. Potencies of the AMPD Inhibitors across Recombinant
Enzymes and Tissue Homogenates with IC50 Values Given in
Micromolar
Enzyme/Tissue
Homogenate Compound 2 Compound 3 Compound 4
hAMPD1 9.2 ± 2.0 (n = 4) 0.038a 0.024a
rAMPD1 5.8a 0.027a 0.020a
mAMPD1 4.5a 0.024a 0.020a
Rat MH 32 ± 12 (n = 6)b 0.016 ± 0.002
(n = 4)
0.0055 ± 0.0009
(n = 4)
ob/ob MH 7.7 ± 1.3 (n = 4) 0.024 ± 0.001
(n = 4)
0.0014 ± 0.0005
(n = 4)
hAMPD2 32a 0.016a ND
rAMPD2 32 ± 2.2 (n = 2) 0.57 ± 0.081
(n = 2)
0.30a
Rat LH 7.7 ± 0.7 (n = 2) 0.29 ± 0.027
(n = 6)
0.089 ± 0.019
(n = 4)
ob/ob LH >10 0.20 ± 0.033
(n = 4)
0.023 ± 0.007
(n = 4)
hAMPD3 7.3a 0.075 ± 0.001
(n = 2)
ND
rAMPD3 44 ± 5.8 (n = 2) 0.40 ± 0.017
(n = 2)
ND
H, human; r, rat; m, mouse; ND, not determined, MH, muscle homoge-
nate, LH, liver homogenate.
aIC50 value resulting from four-parameter logistic fitting to duplicate data.
bDetermined at 10 mM AMP.
Figure 3. Pharmacological Inhibition of AMPD in Primary Hepato-
cytes
(A) Fructose induced ATP depletion in primary rat hepatocytes. Freshly pre-
pared rat hepatocytes kept in suspension were ATP-depleted by a 5 min in-
cubation with fructose (2.8 mM) that induced IMP formation.
(B) IMP levels in ATP-depleted hepatocytes treated with AMPD inhibitors. cpd,
compound.
(C) Effects on AMP levels in hepatocytes treated with AMPD inhibitors.
The values are mean ± SD. #, below the detection limit of the system; *p < 0.03
compared with the DMSO controls in a two-tailed Student’s t test.
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were not significantly altered by compound 3 treatment. The
HOMA insulin resistance index was not significantly different
between the vehicle- and compound 3-treated groups. Lack
of treatment-induced improvement in average diurnal glucose
control was supported by similar fructosamine levels in the
compound 3-treated group compared with the vehicle control
group (Table S1). Compound 3 treatment did not affect plasma
levels of triglycerides (TGs) or free fatty acids. Based on the
plasma levels shown in Table S1, the estimated concentration
of compound 3 unbound in plasma is 80-fold higher than the
IC50 of mouse AMPD1 (Table 2).
Ampd1-Deficient Mice
Ampd1-deficient animals (Ampd1 knockout [KO]) were gener-
ated by a targeted deletion at the Ampd1 locus (Figure S2A)
and positive embryonic stem (ES) cell clones were identified
by Southern blot analysis (Figure S2B). Ampd1 deficiency
was confirmed by RT-PCR analyses of RNA derived from skel-
etal muscle from wild-type, heterozygous, and homozygous
Ampd1 mutant mice (Figure S3C). As expected, no expression
of Ampd1 was observed in the Ampd1 KO mice (Figure S3C).
The western blot analysis presented in the accompanying paper
by Plaideau et al. (2014) confirmed that no AMPD1 protein or
additional downstream translational products were present in
extensor digitorum longus (EDL) and soleus muscle from the
Ampd1 KOmice. Fainter, 50,000-Mr bandswere observed in im-
munoblots of both EDL and soleus muscle from wild-type mice.
However, these bands were also present in the same blots for
EDL and soleus muscle from Ampd1 KO mice. One would not1490 Chemistry & Biology 21, 1486–1496, November 20, 2014 ª2014expect to see these bands in both wild-type and Ampd1 KO
muscles in the event of odd splicing from exons 1–6 to exon
14 in the knockout. AMPD activity was also measured in skeletal
muscle homogenates from Ampd1 KO (n = 8) and wild-type
(n = 8) mice using the GDH-coupled assay as described above.
Muscles from Ampd1 KOmice had undetectable AMPD activity,Elsevier Ltd All rights reserved
Table 3. Four-Hour Fasting Blood Glucose and Insulin and
Incremental AUC for Glucose and Insulin during an OGTT in
Vehicle-Treated, Compound 2-Treated, and Compound
3-Treated DIO Mice
Vehicle Compound 2 Compound 3
Body weight (g) day 0 50.1 ± 0.8 49.2 ± 0.6 49.7 ± 0.4
Body weight
reduction (g) day 14
2.2 ± 0.7 2.4 ± 0.5 1.4 ± 0.4
Basal glucose (mM) 8.9 ± 0.3 8.8 ± 0.4 10.0 ± 0.3a
Basal insulin (pg/ml) 2.9 ± 0.1 3.0 ± 0.3 3.7 ± 0.3a
HOMA (mM 3 pg/ml) 25.7 ± 1.2 26.6 ± 3.1 37.6 ± 4.2a
Glucose inc AUC 446 ± 53 347 ± 35 436 ± 64
Insulin inc AUC 312 ± 52 341 ± 52 263 ± 45
Test compound (mM) 7.8 ± 0.9 9.7 ± 1.2
n = 5–6/group.
ap < 0.05 versus vehicle. Values are mean ± SEM.
Figure 4. Metabolic effects because of deletion of the Ampd1 gene
in mice.
(A) Body weight gain from 4–14 weeks of age in standard chow-fed (SCD) wild-
type mice (n = 8, filled circles), Ampd1 KO mice (n = 8, filled circles), HFD-fed
wild-type mice (n = 8, filled squares), and Ampd1 KO mice (n = 8, open
squares). Statistical analysis was performed using repeated Student’s t test.
(B and C) Oral glucose tolerance test in chow-fed wild-type mice (n = 7, filled
circles), Ampd1 KO mice (n = 7, open circles), HFD-fed wild-type mice (n = 7,
filled squares), and Ampd1 KO mice (n = 7, open squares). The results are
presented as mean ± SEM. Statistical analysis of AUC values was performed
using Student’s t test.
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levels of compound 3-sensitive deaminase activity (Figure S2C).
Intercrossing of male and female mice heterozygous for the
Ampd1 mutation resulted in offspring of normal litter sizes. Of
the male offspring, 20%were homozygous, 51%were heterozy-
gous, and 29% were wild-type mice. The Ampd1 KO mice were
healthy and appeared normal, displaying no obvious adverse
phenotype over the course of the study. No significant differ-
ences in body weight gain were observed between the cohorts
of Ampd1 KO and wild-type mice fed the chow diet or those
on a high-fat diet (HFD) (Figure 4A). As expected, the wild-type
mice on an HFD displayed a greater body weight gain compared
with those fed the chow diet so that, at study termination, the
former were more than 50% heavier (p < 0.001) (Table S2). The
chow-fed Ampd1 KO mice had increased body length at
30 weeks of age (but not at earlier time points) compared with
the chow-fed, wild-type control animals (wild-type, 10.5 ±
0.0 cm; Ampd1 KO mice, 10.7 ± 0.1 cm; p < 0.05). Body length
did not differ significantly between the cohorts fed an HFD at
any time point assessed (data not shown). Assessment of
body composition was performed in 17- and 30-week-old ani-
mals and revealed no significant difference in any measured
parameter, including absolute and relative lean body mass,
body fat mass, bone mineral content, or bone mineral density,
between Ampd1 KO and wild-type mice, neither when on
chow or an HFD (data not shown). The mice were analyzed
with respect to energy intake, fecal energy output, energy
expenditure, respiratory exchange ratio, core body temperature,
and locomotor activity. The Ampd1 KOmice displayed no signif-
icant alterations in any of these parameters when compared with
the wild-type controls when fed chow or an HFD (energy expen-
diture data (Oxymax) are shown in Figure S3). In addition, the
Ampd1 KO mice displayed no sign of depression or anxiety
when compared with the wild-type mice, irrespective of diet.
No significant differences were observed in an open field
locomotor activity test between the chow-fed Ampd1 KO and
wild-type mice. However, the Ampd1 KO mice on an HFD had
significantly increased horizontal and total activity, increased
rearing time, and less time spent in corners in the open field
box compared with the HFD-fed wild-type mice.Chemistry & Biology 21, 1486–149Glucose tolerance was assessed by an OGTT. There was no
significant difference in fasting blood glucose, fasting insulin
levels, or HOMA index between Ampd1 KO and wild-type mice
on a chow diet or between Ampd1 KO and wild-type mice6, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1491
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AMPD Inhibitors and Genetic Ampd1 Deletionon an HFD (Figure 4B). Also, no significant differences were
observed in terms of blood glucose or insulin responses (AUC)
between Ampd1 KO and wild-type mice on either diet (Fig-
ure 4B). There was a slight trend toward increased insulin levels
(AUC, p = 0.083) and HOMA index (p = 0.17) in chow-fed Ampd1
KO mice compared with wild-type mice.
At sacrifice, no significant differences were observed in body
weight or in the absolute or relative (to bodyweight) weight of liver
and heart between Ampd1 KO and wild-type mice fed a chow
diet. The Ampd1 KOmice fed an HFD displayed a higher relative
weight of the heart, whereas the body and liver weights were un-
altered compared with HFD-fed wild-type mice. Mice on an HFD
displayed increased body weight and liver weight, regardless of
genotype, compared with chow-fed mice, as expected (Table
S2). Table S2 also shows the results of the biochemical analysis
of plasma samples collected at termination. Insulin levels were
increased significantly in chow-fed Ampd1 KO mice compared
with chow fed wild-typemice (Table S2). There was a slight trend
toward increased insulin levels in HFD-fed Ampd1 KO mice
compared with the HFD-fed wild-type mice (2.2-fold increase,
p = 0.08). Glucose levels were not different in the wild-type or
Ampd1 KO mice on either diet. No differences were observed
in any of the other plasma parameters assessed between
Ampd1 KO and wild-type mice on any of the diets (Table S2).
DISCUSSION
Chronic nutrient overload in combination with a sedentary life-
style is known to contribute to metabolic inflexibility and insulin
resistance in peripheral tissues. Long-term energy excess is
postulated to cause oxidative stress and modulate pathways
regulated by cellular energy sensors such as AMPK. Examples
of AMPK-regulated pathways sensitive to energy status are
cellular recycling mechanisms including autophagy, mitophagy,
and antioxidant defense enzymes (Egan et al., 2011; Greer et al.,
2007; Kim et al., 2011; Lee et al., 2010; Shang et al., 2011; Zhao
and Klionsky, 2011). Drug treatments mimicking feeding-fasting
cycles in terms of intracellular energy sensing (e.g., AMPK acti-
vation) therefore have the potential to attenuate some of the
negative effects caused by continuous oxidative stress and sub-
sequent cellular damage. Difficulties in identifying tissue-selec-
tive and safe direct activators of AMPK have sparked an interest
in finding alternative, indirect mechanisms to increase AMPK
activity. Metformin and thiazolidineiones, along with other
weak metabolic inhibitors, have been demonstrated to increase
intracellular AMP:ATP ratios with downstream AMPK activation
as part of their biological effects (reviewed in Hardie et al.,
2012a; Zhang et al., 2009). In this investigation, we attempted
to inhibit the breakdown of AMP by AMPD rather than to in-
crease AMP by restricting mitochondrial ATP synthesis. HTS
of an AstraZeneca R&D compound collection using recombi-
nant human AMPD1 yielded a series of inhibitors that, after
further optimization, generated compounds suitable for in vivo
testing (Figure 2). Chiral separation of an AMPD inhibitor race-
mate resulted in two pure enantiomers, compound 2 and
compound 3, with a large separation in potency, making them
suitable for biological concept testing and target validation. A
panel of in vitro and ex vivo assays confirmed the potency of
the tested compounds, and they were dosed in vivo to give1492 Chemistry & Biology 21, 1486–1496, November 20, 2014 ª2014exposure levels several-fold above the determined IC50 values
for AMPD1.
Critical for AMPD inhibitor-induced AMP accumulation is a
high enough basal flux through AMPD to IMP. Data from human
subjects with a defect in AMPD1 show that there is a trend
toward an elevation of both AMP and ADP in resting muscle,
but it is not clear whether this relatively small increase would
translate into any significant AMPK activation (Norman et al.,
1995). However, individuals with AMPD1 deficiency also display
a faster loss of muscle power during sprint exercise compared
with normal subjects (Fischer et al., 2007), an observation that
is not in line with the postulated exercise mimetic effects
described for AMPK activators (Narkar et al., 2008). Therefore,
previously reported human data do not give a clear answer to
whether inhibition of AMPD in a resting muscle would result in
any physiologically relevant elevation of AMPK activity.
Compounds 3 and 4 both inhibited IMP formation induced by
ATP depletion and simultaneously increased AMP levels in hepa-
tocytes. In addition, AMPD activity in homogenates of mouse
and rat muscle and liver was potently blocked by the com-
pounds, confirming their ability to inhibit the enzymes in the
context of endogenous tissue complexity. Our investigation
also included a multiple dosing study using ob/ob mice as a
model of obesity and diabetes. This model has been proven sen-
sitive and predictive in terms of insulin sensitization by other well
characterized antidiabetics, such as the peroxisome proliferator-
activated receptor agonists (Ljung et al., 2002). Although our
multiple dosing protocol in mice resulted in exposure levels
high enough to ensure almost full 24-hr coverage regarding inhi-
bition of AMPDs, we were unable to detect any robust effects on
metabolism in either ob/ob or DIO mice. In the DIO mice, fasting
glucose and insulin levels were slightly elevated following
2 weeks of repeated dosing with AMPD inhibitor compound 3,
but no difference was seen in either the glucose or insulin AUC
following the OGTT. In the Ampd1-deficient mice, insulin levels
were increased in the chow-fed group but not in the HFD-fed
group compared with wild-type mice. The Ampd1-deficient
mice displayed no other alteration in any of themetabolic param-
eters assessed, including body weight; body fat mass; and
energy intake, uptake, or expenditure, either when fed a normal
chow diet or when on an HFD. The increased insulin levels seen
in the Ampd1 KO mice and after AMPD inhibition in DIO mice
suggest an association between the loss of Ampd1 gene
function and increased plasma insulin levels. Goodarzi and col-
leagues have shown, in Mexican Americans, that different hu-
man haplotypes for AMDP1 result in either increased or
decreased insulin clearance but with no effect on fasting insulin
levels or glucose infusion rate during clamp studies (Goodarzi
et al., 2005). Other human population studies have, however,
demonstrated no or, instead, protective effects in terms of prev-
alence of type 2 diabetes in subjects carrying the inactivating
AMPD1 C34T polymorphism, making interpretations difficult
(de Groote et al., 2006; Safranow et al., 2009).
The widely used antidiabetic drug metformin was also tested
for inhibitory effects on rat recombinant AMPD1 and AMPD2.
As seen in Figure S1, 20 mM metformin was required to cause
any significant inhibition of enzyme activity. Pharmacological
doses of metformin generally result in peak exposure levels
below 4 mg/l (30 mM) (Klepser and Kelly, 1997), requiringElsevier Ltd All rights reserved
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reach concentrations high enough to inhibit AMPD activity.
Although metformin is known to be a substrate for transporters
such as the organic cation transporter 1 (Oct1) in hepatocytes,
the reported level of metformin accumulation because of active
transport via Oct1 in mouse liver is only 4- to 30-fold higher
(Shu et al., 2007; Wang et al., 2002). Metformin is, therefore,
not likely to reach the intracellular concentrations required to
inhibit AMPD, at least not in hepatocytes.
In summary, we conclude that basal AMPD flux in liver and
muscle is nondetectable to low at energy excess, a state rep-
resented in the chronic mouse disease models and, most likely,
in the majority of the obese and type 2 diabetes patient popu-
lation. In rat epitrochlearis muscle subjected to mild contrac-
tions in vitro, AMPK activation could be potentiated by AMPD
inhibitors, but this did not lead to an enhancement of glucose
uptake (see the accompanying paper by Plaideau et al.,
2014). Therefore, the concept of inhibiting AMPD as a means
of elevating intracellular AMP levels and inducing AMPK activity
is not supported by this study and is not likely to be a viable
approach for improving insulin sensitivity and treating type 2
diabetes in patients. However, the AMPD inhibitors presented
here will hopefully be useful tools for explorative work in
different biological contexts, such as disease states with
confirmed energy depletion and adenine nucleotide break-
down, but may also serve as starting points in the search for
new and more efficient herbicides (Bojack et al., 2001; Lindell
et al., 1999, 2010).
SIGNIFICANCE
We identified potent small molecule inhibitors of human and
rodent AMPDs. Chiral separation of an inhibitor racemate
gave rise to a pair of enantiomers, compound 2 and com-
pound 3, with a wide separation in potency for inhibiting
the AMPDs, thus providing an attractive pair of tool com-
pounds for validation and mechanistic studies. The discov-
ered chemical series represented by compound 3 and
compound 4 in this study was shown to be bioavailable
and cell-permeable, with potencies translating from recom-
binant enzyme assays to inhibition of native enzyme activity
in tissue extracts. Although it is well established that treat-
ments lowering cellular energy status will cause changes
in adenine nucleotide levels and, subsequently, activate
AMPK, it has not been elucidated whether blockade of
AMP breakdown via the AMPDs under normophysiological
conditions would mimic a drop in energy charge. In this
study, we applied both pharmacological and genetic inacti-
vation of AMPD to test this hypothesis. Our investigation
demonstrated the limited impact of AMPD inhibition on
IMP and AMP levels under conditions of excess energy.
Consequently, none of the postulated antidiabetic effects
because of AMPK activation could be observed after multi-
ple dosing of the inhibitors to DIO or ob/ob mice or in mice
with a deletion of the gene encoding the muscle AMPD
isoenzyme. However, the described AMPD inhibitors would
be important tools for further investigating AMPD function
in disease states with confirmed energy depletion and
adenine nucleotide breakdown.Chemistry & Biology 21, 1486–149EXPERIMENTAL PROCEDURES
Expression and Purification of Recombinant AMPD Enzymes
DNA fragments encoding full-length human AMPD1 (NCBI Reference
Sequence (RefSeq) database ID code NM_00036), rat AMPD1 (ID code
NM_138876), rat AMPD2 (ID code NM_001101681), and rat AMPD3 (ID code
NM_031544) were cloned into the baculovirus expression vector pFastBac-1
(Invitrogen) between restriction sites BamHI and XhoI, respectively. Human
AMPD2 (NCBI RefSeq database ID code NM_004037) and AMPD3 (ID code
NM_001172430) were cloned into the vector pFastBac-1 between restriction
sites BamHI and XbaI. Correct DNA sequences were confirmed by DNA
sequencing. High-titer virus stocks were prepared in Sf9 (Spodoptera frugi-
perda) insect cells according to the manufacturer’s protocol (Invitrogen).
Recombinant AMPD1, AMPD2, and AMPD3 enzymes were expressed in
Sf21 (Spodoptera frugiperda) cells incubated with Sf-900 II SFM medium
(Invitrogen) for 72 hr in a 1 l shaking flask and purified from extracts prepared
in buffer containing 10 mM potassium phosphate (pH 6.6), 500 mM KCl,
0.1% (v/v) mercaptoethanol, 5 mg/ml leupeptin, and 10 mM E-64 by column
chromatography on Whatman P11 cellulose phosphate, as described previ-
ously (Haas and Sabina, 2003). Protein identities were confirmed by MALDI-
TOF/TOF mass spectrometry.
AMPD High-Throughput Screening Assays
GDH was purchased from Roche, and all other material was purchased from
Sigma, unless stated otherwise. Microtiter plates were from Greiner. AMPD1
was added to buffer A (50 mM HEPES, 150 mM KCl, 5 mM MgCl2, and
0.5 mM glutathione [pH 7.4]) to a concentration of 10 nM. A substrate mix con-
sisting of 2mMNADPH, 6mM a-ketoglutarate, 8mMAMP, and 15UGDHwas
prepared in buffer A.
Assay ready plates were prepared by adding 50 nl of compounds to 1,536-
well clear plates. HTSwas performed using a bench cell robotic system equip-
ped with a Flexdrop dispenser, V-spin centrifuge, and Pherastar detector.
Substrate mix (4 ml) was added to the plate, followed by centrifugation and in-
cubation for 1 hr. Detection was by absorbance at 340 nm following the con-
version of NADPH to NADP+.
Three-point dose-response curves using compound concentrations of 25,
2.5, and 0.25 mM were used to identify statistically relevant hits. To remove
false positives as well as nonspecific promiscuous binders, a counterscreen
was performed where AMPD was replaced by NH4
+. Positive hits in the coun-
terscreen were removed. Further analysis of selected compounds was
performed using a seven-point concentration response, with the highest con-
centration of 62 mM followed by 3-fold dilutions. Selected compounds were
also analyzed in the counterscreen.
Synthesis of AMPD Inhibitors
The designed inhibitors were prepared from commercially available 4-bro-
moarylcarboxylic acid and 4-formylphenylboronic acid by Suzuki coupling, fol-
lowed by reductive amination with racemic 1-(isoquinolin-8-yl)ethanamine.
The enantiomers were separated by preparative chiral high-performance liquid
chromatography (HPLC) (see Supplemental Experimental Procedures for
more detail).
Detection of AMPD Enzymatic Activity
Recombinant AMPD enzyme activity assays were performed in a 384-well
format using the same conditions as described above, except the assay vol-
ume was 80 ml and the AMP concentration for the AMPD2 assay was 8 mM.
Different AMPD enzyme concentrations were used to have linear reactions:
hAMPD1 (4 nM), hAMPD2 (38 nM), hAMPD3 (1 nM), rAMPD1 (116 nM),
rAMPD2 (53 nM), rAMPD3 (31 nM), and mAMPD1 (816 nM).
All experimental procedures involving animals were approved by the Local
Ethics Review Committee on Animal Experiments (Go¨teborg region). Tissues
for measurement of AMPD activity were collected from Inactin-anesthetized
(thiobutabarbital, 120 mg/kg intraperitoneally) male rats (Sprague Dawley),
or isoflurane inhalation-anesthetized male ob/ob mice (see below), or
Ampd1 KO and littermate wild-type mice. The animals were euthanized, and
freeze-clamped wing tongs cooled in liquid N2 were used to collect tissues.
For AMPD assays, tissues were powdered under liquid nitrogen and homoge-
nized (Ultra-Turax for 2 3 20 s) in 10 volumes (volume/wet weight) of buffer6, November 20, 2014 ª2014 Elsevier Ltd All rights reserved 1493
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(pH 7.4), supplemented with 1 tablet of Complete protease inhibitor cocktail/
10 ml (Roche). The crude homogenates were centrifuged at 800 3 g for
5 min at 4C. The supernatants were then further homogenized in a glass/
Teflon homogenizer (15 strikes) on ice and finally cleared by centrifugation at
20,800 3 g (4C) for 10 min for storage at 190C until further use. AMPD
activity was measured using a GDH-coupled 96-well assay with detection of
NADPH oxidation as described above. Extracts (5.5 and 76 mg) of muscle or
liver homogenate protein were added to each well containing 50 mM HEPES,
150 mMKCl, 5 mMMgCl2, and 0.5 mM glutathione (pH 7.4) before starting the
reaction by adding substrate as described above but with final concentrations
of 5 and 10 mM AMP for the muscle and liver assays, respectively. Inhibition
values of 0% and 100% correspond to activities measured in separate control
wells in the presence of 1% DMSO or 100 mM compound 3, respectively.
Assays were performed in a Corning black flat 96-well plate at room temper-
ature using an Infinite M200 plate reader (Tecan) set with a kinetic cycle taking
readings at 1-min intervals after 5 s of orbital shaking and with excitation and
emission wavelengths of 338 and 445 nm, respectively (top reading). The per-
centage of inhibition for the compoundswas calculated in the linear range prior
to depletion of substrate in the 0% control (DMSO). Protein concentration was
determined using the Pierce bicinchonimic acid protein assay kit with bovine
serum albumin as a standard.
Isolation of Rat Hepatocytes
Hepatocytes were isolated from female Sprague-Dawley rats. The rats were
anesthetized with sodium pentobarbital (75 mg/kg). A cannula was inserted
in the portal vein, and the inferior caval vein was opened. The liver was
perfused (25 ml/minute) in situ via the portal vein with Ca2+-free Hank’s
balanced salt solution (HBSS) (pH 7.4) with 0.6 mM EGTA, 10 mM NaHCO2,
and 20 mM HEPES. After 10 min of perfusion, the medium was changed to
HBSS containing 10 mM NaHCO2, 20 mM HEPES, 5 mM CaCl2, and
0.13 U/ml of Collagenase A. Perfusion continued for an additional 7 min before
the liver was removed and placed in a Petri dish with cold Williams medium E
supplemented with 5% (v/v) fetal bovine serum (FBS) and 500U/ml of penicillin
and streptomycin. The liver capsula was gently broken with a sharp instrument
to release cells into themedium. To remove residual tissue, the cell suspension
was filtered through a 250 mm nylon mesh and then through a 100 mm mesh
filter. The cells were divided into two 50 ml Falcon tubes, and cold Williams
medium E containing 5% FBS and 500 U/ml of penicillin and streptomycin
was added up to 50 ml, followed by centrifugation (70 3 g for 3 min) at 4C.
The cells were resuspended in cold Williams medium E supplemented with
5% FBS and 500 U /ml of penicillin and streptomycin, followed by centrifuga-
tion (see above). Cell washing was repeated once before resuspending cells in
20 ml Williams medium E supplemented with 5% (v/v) FBS, 500 U/ml of peni-
cillin and streptomycin, 100 nM Selenit, 0.28 mM vitamin C, 1 nM dexameth-
asone, and 3.6 nM insulin. Cells were counted in a FastRead 102 counting slide
and seeded at a density of 500,000 cells/well in Collagen 1-coated, 12-well
plates. After 4 hr of incubation at 37C, the medium was removed, and new
Williams medium E supplemented with 500 U/ml of penicillin and strepto-
mycin, 100 nM Selenit, 0.28 mM vitamin C, 1 nM dexamethasone, and
3.6 nM insulin was added for serum starvation overnight.
Cell-Based AMPD Assay
Freshly isolated hepatocytes (4.8 3 106 cells/ml) from female Sprague-
Dawley rats were incubated at 37C in assay medium consisting of
HEPES-buffered minimum essential medium (25 mM, Gibco, catalog no.
21011-044) supplemented with 5 mM sodium pyruvate (Invitrogen, catalog
no.11360-039) and 1 mg/ml nonessential amino acids (Invitrogen, catalog
no. 11140). The cells were subjected to gentle swirling and incubated with
0.5 mg/ml (2.8 mM) fructose and 0.1% (v/v) DMSO or the indicated concen-
trations of the AMPD inhibitors. Samples were withdrawn and snap-frozen
before and after 5 min of fructose treatment. Extracts were prepared for
nucleotide measurement using a liquid chromatography (LC) with UV detec-
tion system as described below.
Extraction and Analysis of Nucleotides by HPLC-UV Detection
Extracts from cells in 12-well plates were prepared by the addition of 500 ml of
0.05 M perchloric acid in ice-cold 40% CH3OH by mild vortexing for 15 min.1494 Chemistry & Biology 21, 1486–1496, November 20, 2014 ª2014The cell-free extracts were then transferred to 96-well glass vials, neutralized
with 60 ml 0.44 M (NH4)2HPO4 in water, and evaporated to dryness in HPLC
glass vials at 50C under a stream of N2. The analytes were dissolved in
100 ml water, of which 10 ml was injected onto the HPLC system. Separation
was achieved on a Waters Atlantis T3 column (100 A˚, 3 mm, 3 3 100 mm, cat-
alog no. 186003722) over 20 min using a binary solvent system and the
following gradient program: 0% B from 0–2 min, to 15% B at 10 min, and to
50% B at 20 min. A washout step with 100% B for 5 min and an equilibration
step at 0% B for 5 min were performed prior to the next injection. The
mobile phases were 0.1 M (NH4)2HPO4 buffer (pH 6) in water (A) or 50%
CH3OH (B). Nucleotides in sample extracts and calibration samples were
then determined quantitatively by UV diode array detection at 254 nM. Peak
purity testing was based on absorbance at 248 nm and 262 nm for adenine
nucleotides and nucleosides, respectively. Calibration and quality control
samples were prepared in 1% (w/v) PBS. The detection limit for IMP was
about 1 pmol injected. The LC-UV systemwas a Dionex P580 pump, a Biotech
Model 2003 degasser, CTC Analytics PAL 96-well autosampler (held at 15C),
and a Gynkotek UVD 320S DAD. LC pump pistons were rinsed continuously
using circulating 20% methanol to avoid the formation of crystals from the
buffers.
Repeated Dosing in DIO Mice
Diet-induced obesity was induced by feeding mice (C57BL/6J OlaHsd
female mice, Harlan Netherlands, starting body weight 18–20 g) a 60% fat
diet (D12492, Research Diets) together with a soft chocolate pastry (42%
carbohydrate, 54% fat, and 4% protein [energy %], Delicato Bakverk AB)
for 18 weeks. After the diet pretreatment, all animals were gavaged twice
daily for 2 weeks with vehicle (0.9% w/v NaCl [pH 3]) or with the test com-
pounds compound 2 or compound 3, both at 300 mmol/kg b.i.d. (see Table 2
for mouse in vitro potencies). Body weight was measured repeatedly
throughout the study. After 2 weeks of treatment, an OGTT was performed
on 4 hr fasted mice. Starting at 8 am, the mice were fasted in clean cages
for 4 hr. A sample was collected for analysis of glucose and insulin, followed
by oral gavage with 2 g/kg D-glucose. Repeated blood samples were taken
via the tail vein 15, 30, 60, 90, and 120 min after the glucose challenge. At
each time point, one blood drop was used for glucose measurement
(AccuChek Abbott) and 2 3 3 ml blood was collected for insulin measure-
ments (Ultra Sensitive Insulin ELISA kit, Chrystal Chem with addition of hep-
arin [20 ml. 1 mg/ml] to the sample diluent bottle). The following day, the
animals were sacrificed, and plasma was collected 3 hr after the final dose
for measurement of compound concentrations.
Biochemical Analysis of Plasma
Plasma insulin was determined with a radioimmunoassay (RIA) (mouse Insulin
RIA kit, Millipore). Colorimetric kit methods were used for the measurement of
plasma glucose and lactate (Horiba ABX), triglycerides (Roche Diagnostics),
free fatty acids (Wako Chemicals), D-3-hydroxybutyrate, and fructosamine
(Randox). Liver triglyceride content was determined after tissue homogeniza-
tion in isopropanol. Triglycerides in the supernatant were measured using an
enzymatic colorimetric method (Horiba ABX).
For determining compound concentrations, plasma samples were precipi-
tated with acetonitrile. After centrifugation, the supernatant was diluted with
0.2% formic acid. Analysis was performed on a short reversed-phase HPLC
column with rapid gradient elution and mass spectrometry (MS)/MS detection
using a triple quadruple instrument (Waters Quattro Ultima) with electrospray
ionization and selected reaction monitoring acquisition.
Generation of Ampd1-Deficient Mice
A Lox-P strategy was used to target theAmpd1 locus to generateAmpd1-defi-
cient mice. A 14.5 kb fragment of a C57BL/6 mouse genomic subclone was
used as targeting vector, containing a floxed neomycin phosphotransferase
selection marker cassette after the coding sequence in the UTR and a single
Lox-P site inserted in intron 6 of the Ampd1 locus (illustrated schematically
in Figure S1A). The targeting vector was linearized by using SacII and electro-
porated into C57BL/6 mouse ES cells (derived from C57/J, Genome Systems)
which were then grown in medium containing G-418 (300 mg/ml). The Ampd1-
deficient mouse line was thus established on a pure C57BL/6 genetic back-
ground. The candidate ES cell clones were screened by PCR over the shortElsevier Ltd All rights reserved
Chemistry & Biology
AMPD Inhibitors and Genetic Ampd1 Deletionarm homology of the construct, and the gene targeting event was further
confirmed by Southern blot analyses using BamHI restriction enzymes (Fig-
ure S1B). One clone was expanded and injected into BALB/c blastocysts to
generate chimeric mice. Chimeric offspring was bred with C57BL/6N mice
(Charles River Laboratories) to produce black-coated offspring. The following
primers were used to identify offspring with the targeted allele: forward neo-
specific primer (F) 50-TCCTGCCGAGAAAGTATCCATCAT30 together with a
reverse primer within the short arm homology (R1): 50-CTCGAAGGCTTGCG
CTACCACTAA30. Heterozygous mice carrying Lox-P DNA sites were bred
with ROSA26Cre mice (Soriano, 1999) that had been backcrossed more
than 20 generations with C57BL/6Nmice (Charles River) to generate heterozy-
gous Ampd1-deficient mice. The mice were identified using the genotyping
primers 50-TTGAAGCATCTGAAAGTGGAGGGA30, 50- CATAAGAGGGAGTG
GTTGCAGGAA-30, and 50-TGGACCATCACGATTCATTTGTTA30 and re-
sulted in 838 bp products for the recombined allele and 254 bp products for
the wild-type allele. Heterozygous Ampd1-deficient mice were intercrossed
to generate homozygous Ampd1-deficient animals that proved to be viable.
To verify the Ampd1-null mutation, total RNA was prepared from skeletal
muscle of 5-week-old homozygous, heterozygous, and wild-type littermates
using the RNA STAT-60 kit according to the manufacturer’s instructions
(Tel-Test). cDNA was synthesized using Superscript TM II RNase H - reverse
transcriptase and random hexamer primers (Life Technologies). RT-PCR
was performed using the primers 50-ATCTTACCATATTGACGCCGACAG-30
(forward) and Ex 50-TGCACCCACCTCCTTGATGATAGT-30 (reverse) (Fig-
ure S1C) to show that exons 7–13 were deleted in the Ampd1-deficient
mice. The Ampd1 heterozygous mouse colony was expanded by breeding
with C57BL/6N mice (Charles River) and heterozygous intercrossing was per-
formed to produce Ampd1 homozygous experimental and wild-type littermate
control cohorts having a pure C57BL/6N genetic background.
Male Ampd1-deficient and control mice were housed individually in a
temperature-controlled room (22C) with a 12 hr light-dark cycle. They had
free access to normal chow diet (R36, Lactamin AB) and water. The R36
chow diet contains (energy %) 22.9% protein, 67.1% carbohydrate, and
9.6% fat with a total energy content of 3.08 kcal/g. For the HFD experiments,
the HFD used was D12492 (Research Diets) containing (energy %) 60%
fat, 20% carbohydrates, and 20% protein with a total energy content of
5.20 kcal/g.
In Vivo Phenotypic Screening
The Ampd1-deficient (Ampd1 KO) mice and control cohorts (wild-type) were
studied in a series of tests from 4–31 weeks of age. Body weights were re-
corded weekly from 4–14 weeks of age and then again at study termination.
At 8 weeks of age, the mouse cohorts were subdivided into two groups, and
one cohort of Ampd1 KO mice (n = 8) and one cohort of wild-type mice
(n = 8) were switched to the HFD, whereas a second cohort of Ampd1 KO
mice (n = 8) and wild-type mice (n = 8) remained on the chow diet. The
HFD was provided over a 23-week period. An OGTT was performed on
19- to 20-weeks-old mice (12 weeks after HFD introduction) as described
previously (Bjursell et al., 2007). Assessment of behavior was performed
on 16- to 18-week-old animals as described previously (Gerdin et al.,
2006). All mice were terminated at 31 weeks of age, 23 weeks after the intro-
duction of the HFD for the intended groups. The mice were fasted for 3 hr
and then anaesthetized by isoflurane inhalation. Blood was collected in
EDTA-coated tubes by cardiac puncture. Blood plasma was separated by
centrifugation (2500 rpm, 10 min, 4C) and snap-frozen in liquid N2. The heart
and liver were blotted and weighed. For more details, see Supplemental
Experimental Procedures.
Statistical Analyses
The results are presented asmean ± SEM. For the compound repeated dosing
studies in DIO and ob/ob mice, comparisons were made between test sub-
stance-treated mice and the vehicle group using unpaired Student’s t test. A
value of p < 0.05 was considered statistically significant. For the wild-type
versus Ampd1 KO studies, statistical calculations for pairwise single parame-
ters measured at one time point were performed using Student’s t test.
Statistical calculations of parameters measured over time were performed
by two-way ANOVA. p < 0.05 between the groups was considered to be
statistically significant.Chemistry & Biology 21, 1486–149SUPPLEMENTAL INFORMATION
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